Publication
Comparison of metabolic abnormalities and clinical lipodystrophy 48 weeks after switching from HAART to Trizivir versus continued HAART: the Trizal study
| dc.contributor.author | Lafeuillade, A | |
| dc.contributor.author | Clumeck, N | |
| dc.contributor.author | Mallolas, J | |
| dc.contributor.author | Jaeger, H | |
| dc.contributor.author | Livrozet, JM | |
| dc.contributor.author | Ferreira, MS | |
| dc.contributor.author | Jonhson, S | |
| dc.contributor.author | Cheret, A | |
| dc.contributor.author | Antoun, Z | |
| dc.contributor.author | European Trizal team. | |
| dc.date.accessioned | 2013-12-13T14:50:21Z | |
| dc.date.available | 2013-12-13T14:50:21Z | |
| dc.date.issued | 2003 | |
| dc.description.abstract | PURPOSE: To analyze the evolution of clinical lipodystrophy (LD) and metabolic abnormalities in patients continuing to receive HAART versus patients switched to Trizivir (zidovudine, lamivudine, abacavir) after 48 weeks. METHOD: Patients treated with HAART >6 months with plasma HIV-1 RNA viral load (VL) <400 copies/mL and <50 copies/mL at screening were randomly assigned to continue HAART (103 patients) or to receive Trizivir (106 patients). Clinical LD was evaluated using a standardized patient questionnaire only at baseline, weeks 4 and 8, and then every 8 weeks until Week 48. Laboratory evaluation was performed every 4 weeks. RESULTS: The proportion of patients exhibiting >or=1 LD symptom at baseline was 40% in the Trizivir arm and 50% in HAART arm (difference not significant). After 48 weeks, the prevalence was 28% and 42% respectively (p =.03), and the median number of LD symptoms per patient was 2 in the Trizivir arm and 4 in the continued HAART arm (p =.016). Median decreases in cholesterol levels over the 48-week study period were greater in the Trizivir arm than in the continued HAART arm (-0.80 vs. -0.44 mmol/L; p lt.001). Median triglyceride levels decreased in the Trizivir arm but increased in the continued HAART arm (-0.17 and +0.01 mmol/L; p =.006). Suppression of VL was maintained in most patients with no differences between the two arms. CONCLUSION: A switch from "standard" HAART to Trizivir was associated with an improvement in clinical LD and blood lipid abnormalities after 48 weeks. | por |
| dc.identifier.citation | HIV Clin Trials. 2003;4(1):37-43. | por |
| dc.identifier.uri | http://hdl.handle.net/10400.23/560 | |
| dc.language.iso | eng | por |
| dc.peerreviewed | yes | por |
| dc.subject | Terapêutica Anti-Retrovírica | por |
| dc.subject | Terapêutica Anti-Retrovírica de Elevada Potência | por |
| dc.subject | Síndrome de Lipodistrofia Associada ao HIV | por |
| dc.subject | Infecções por HIV | por |
| dc.subject | Lamivudina | por |
| dc.subject | Zidovudina | por |
| dc.subject | Doenças Metabólicas | por |
| dc.title | Comparison of metabolic abnormalities and clinical lipodystrophy 48 weeks after switching from HAART to Trizivir versus continued HAART: the Trizal study | por |
| dc.type | journal article | |
| dspace.entity.type | Publication | |
| rcaap.rights | openAccess | por |
| rcaap.type | article | por |